GNRH1 and neoplasm: To minimize toxicity in noncancerous tissues, tumor-specific ligands are used to modify vectors to increase the selectivity of the delivery of drugs, such as folate and LHRH analogs (Ledermann et al., 2015; Tambe et al., 2017).